Abbott Laboratories

New York Stock Exchange
Back to all articles
Very Bullish +85

Abbott (ABT) Finalizes $21 Billion Exact Sciences (EXAS) Takeover

AI-generated analysis

🏛️ Abbott (ABT) successfully closed its $21 billion acquisition of Exact Sciences (EXAS) on March 23, 2026.

💰 All outstanding shares of Exact Sciences were converted to cash at a price of $105.00 per share, subject to certain exclusions.

📉 Nasdaq suspended trading in EXAS shares prior to market open on the closing date, with final public trading occurring on March 20, 2026.

⛔ The entire board and executive management team of Exact Sciences resigned following the completion of the merger.

🚀 Share prices for Exact Sciences surged approximately 130% over the twelve months leading up to the acquisition offer.

📊 Exact Sciences had a market capitalization near $20 billion with recent annual revenues of $3.25 billion against a net loss.

💼 The deal was executed through a merger with Badger Merger Sub I, Inc., an entity controlled by Abbott Laboratories.

🏦 Approximately $21 billion in transaction value was funded using Abbott's existing cash reserves combined with borrowed funds.

✅ Regulatory clearances from all necessary authorities were obtained prior to the official closing date of March 23, 2026.

👥 Stockholders voted to approve the merger, with 67.56% of votes cast in support of the transaction agreement.

🔄 Convertible debt securities issued by Exact Sciences are now set to convert exclusively into cash payments based on the acquisition price.

👉 Incentive plan equity awards, including stock options and RSUs, were either converted to cash or transferred to Abbott with adjustments.

📝 Corporate governing documents were amended as part of the transaction closure process.

🏥 Abbott states the acquisition solidifies its position as a leader in oncology screening and diagnostic testing services.

⚖️ Recent federal legislation establishing Medicare reimbursement for multi-cancer early detection tests was identified as a key benefit.

Bullish Signals
  • Abbott officially closed its $21 billion acquisition of Exact Sciences on March 23, 2026, solidifying its position as a frontrunner in oncology screening and diagnostic testing.
  • Exact Sciences shares surged approximately 130% in the twelve months preceding Abbott's offer, demonstrating strong investor confidence leading up to the deal.
  • The transaction was executed via a merger with Badger Merger Sub I, Inc., fully controlled by Abbott, with stockholders receiving $105.00 cash per share for a total value supported by existing cash reserves and borrowed funds.
  • Recent federal legislation has created a Medicare reimbursement framework for multi-cancer early detection screening tests, providing a critical regulatory advancement that Exact Sciences had identified as essential for advancing cancer detection capabilities.
  • 67.56% of votes cast previously supported the transaction agreement, indicating strong stockholder alignment with the strategic move to serve millions more patients worldwide.
Risk Factors
  • Abbott is financing a $21 billion acquisition partly through borrowed funds, increasing leverage and financial risk.
  • Exact Sciences posted a net loss of $1.10 per share against $3.25 billion in revenue over the trailing twelve months, indicating significant operational unprofitability prior to the merger.
  • Wall Street analysts forecasted earnings of $1.27 per share for the upcoming fiscal year, suggesting management may have been unable to meet these positive market expectations with recent performance data showing a loss.
  • The entire board and executive team of Exact Sciences stepped down following the merger, raising concerns about potential instability or a lack of leadership continuity during the integration process.
  • Approximately 32% of stockholders voted against the merger agreement (as only 67.56% supported it), indicating significant dissent within the investor base.
  • Dissenting stockholders and certain excluded categories were exempted from the standard $105.00 per share cash conversion, creating an uneven exit value for a portion of shareholders.
  • Nasdaq trading was suspended on March 23, 2026, with final public market trading ending on March 20, limiting liquidity and potentially trapping investors before the deal closed.
Full Analysis
Abbott Laboratories (ABT) officially closed its $21 billion acquisition of Exact Sciences (EXAS) on March 23, 2026, completing a merger that saw all shares of the target company exchanged for $105.00 cash per share. The transaction was executed through a merger with Badger Merger Sub I, Inc., an entity fully controlled by Abbott, utilizing both existing cash reserves and borrowed funds. Precursor trading on the public market ceased after March 20, 2026, as Nasdaq suspended trading before the opening bell on March 23, following a formal request to delist from the exchange. Dissenting stockholders and certain excluded categories were exempted from the cash conversion, and the final aggregate value of the deal may see minor adjustments based on the conversion of outstanding convertible debt instruments at predetermined rates. Following the merger completion, Exact Sciences' entire board and executive team stepped down, with all directors tendering their resignations and corporate officers exiting their roles. Equity compensation plans, including stock options, restricted stock units, and deferred stock units, were addressed by converting awards into cash payment rights or transferring them to Abbott with adjusted provisions. The deal received approval from stockholders, with 67.56% of votes cast supporting the agreement, after necessary regulatory clearances were secured prior to closing. Prior to the acquisition, Exact Sciences had a market capitalization near $20 billion but recorded a net loss of $1.10 per share over the trailing twelve-month period against revenues of $3.25 billion, while Wall Street had forecasted earnings of $1.27 per share for the upcoming fiscal year. The acquisition significantly strengthens Abbott's position as a frontrunner in oncology screening and diagnostic testing, positioning it to serve millions more patients worldwide. The combined entity now owns Exact Sciences as a subsidiary, leveraging recent federal legislation that established a Medicare reimbursement framework for multi-cancer early detection tests—a development Exact Sciences had identified as critical for advancing cancer detection capabilities before the deal was finalized. Abbott plans to file documentation to terminate its Securities and Exchange Commission reporting requirements once the delisting process is fully completed.